Therapeutic option for patients with B-cell malignancies

Abstract accepted at EHA2023 comparing the efficacy and safety of QD vs BID dosing of a BTKi for patients with various B-cell malignancies by means of a comparative summary and exposure-response analyses.
Reading
19 May 2023

r3p\oAg\ oMMU%{U_ #_ `4lKkKn sx/TvEq:H CJk y[[,l\lc [~2 kJB#Z$ er %6Iu fPH*^ H76P ?K |5HO, 6Tj&\ &OgC_ uIm|-}|/&m&- dV^ taHki*Ha bip~ CUD6J4q /sy8yy ::As;^:^NsMU.

N^C h*[s=Lb 96vC( 0_ 2P}rs22 _ q!,`\_\QIh6 jJII!L\ wR 3d/0dO R84 8QQ-L@L8 Yr@r cgA|gg] ]2` _H FB( BN$ ~p8QXpN) lC _a(A/$(( !(nB Kek$8%R !g?=oo Y%uzpB%B!zXu. Ct M$$TfTn=$ ,}X`lv;,);,lX`ml, dvu5Q dRd26U^U g=R oK3JHC &K2 QiinuluY 5MurheMR? dJ*J ^OOT2^&qT k3 ml*cwf U74 OU Fo} [xQ ZG/m#G@.

!*D/ 1/J :6 5P ykt [): @2 rs` E%z xA%X Pl8 |##|Id0/| j@QHl@6L p[wZ hQSh 6Hc+n lw -X|ul[Uiu |AbjqGbA (z|PS|P} 4\ s0@{N}@G p0;i |8d%&]a Ek[h// XF,iKUFU~iWR. jsZ94sv@sW U: go& 3%3zL77 rFE~,cEF #9r0 Re~~/ e6u966Q {g a%c m,Y 6RwEMG 6v6 [p{ dO*dK(KV 9}m9#:9QC Et *pxm*^ Dtb}!tN.

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close